MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2025.06.001

Медицинская библиотека · American heart journal · 2025

Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial.

Khan Mirza S, Sauer Andrew J, Green Cynthia L, McDermott Jaime, Khan Muhammad Shahzeb, Chaudhry Sunit-Preet, Haghighat Amir R, Bennett Mosi K, Martyn Trejeeve, Shah Hirak, Govil Ashul, Stanis Tom, Albert Nancy M, DeVore Adam D

СтатьяПротокол клинического исследованияПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Among patients with heart failure (HF), guideline-directed medical therapy (GDMT) remains underutilized. Remote digital interventions may facilitate rapid initiation and uptitration of GDMT; however, potential benefits have not been evaluated in well-powered trials. The VITAL-HF (Virtual Care to Improve Heart Failure Outcomes) trial assessed the safety and efficacy of a remote, digital intervention targeting GDMT optimization versus usual care in participants with HF with reduced ejection fraction (HFrEF).

METHODS

VITAL-HF was a multicenter, randomized-controlled trial of 178 participants with HFrEF. Eligibility included smartphone access, English proficiency, and left ventricular ejection fraction ≤40%. Participants were randomized to receive either the remote, digital intervention (Story Health HF GDMT Titration Program) or usual care for 6 months. The primary outcome was change from baseline in GDMT using the HF Collaboratory Score (HFC), an expert-defined score integrating use and dose of prescribed GDMT. Secondary outcomes included healthcare visits related to symptomatic hypotension, hyperkalemia, and angioedema.

RESULTS

The median age was 66.4 (Q1-Q3: 56.1-73.1) years and 38.8% were female. Major comorbidities included hypertension (71.3%), coronary artery disease (45.5%), atrial fibrillation/flutter (31.5%), and type 2 diabetes (28.1%). At enrollment, the median HFC score was 5 (Q1-Q3: 4-6) with 84.8% on an evidence-based beta blocker, 48.9% on an angiotensin receptor neprilysin inhibitor, 48.9% on a mineralocorticoid receptor antagonist, and 47.2% on a sodium-glucose cotransporter-2 inhibitor.

CONCLUSIONS

The VITAL-HF trial results will provide valuable insights into the safety and efficacy of a remote, digital intervention to improve the use and intensification of GDMT for patients with HFrEF.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05602454; ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT05602454.

Для цитирования: Khan Mirza S, Sauer Andrew J, Green Cynthia L, McDermott Jaime, Khan Muhammad Shahzeb, Chaudhry Sunit-Preet, Haghighat Amir R, Bennett Mosi K, Martyn Trejeeve, Shah Hirak, Govil Ashul, Stanis Tom, Albert Nancy M, DeVore Adam D. Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial.. American heart journal. 2025. DOI: 10.1016/j.ahj.2025.06.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.